Dr. Reddy's Fixed the Syringe, Not the Clock

Dr. Reddy's Fixed the Syringe, Not the Clock

The cliff has stopped hurting — but the margin wasn't earned by selling

For four years, every Dr. Reddy's call has been a negotiation with the Lenalidomide cliff. This quarter the cliff was simply gone: revenue of ₹8,010 crore ($905mn) fell 1.5% year over year but rose 7.4% sequentially, and management's framing has shifted to the ex-Lenalidomide base, which grew double digits across North America, India and emerging markets. India did ₹1,850 crore, up 17.8%, with IPM growth of 21% on a moving quarterly basis against 14.7% for the market. Emerging markets did ₹2,059 crore, up 84% year over year on new launches, acquisitions and currency.

But read the gross-margin line carefully. The 52.1% print is up 562 basis points sequentially — because last quarter was polluted by the semaglutide API provision. Strip that out and this is a recovery to the middle of the guided 50–55% band, not a step-change. “this improvement from last quarter to even this quarter is a combination of the new products and the business mix” — Mannam Venkatanarasimham, Chief Financial Officer · 2026-10-23, the CFO said. Erez Israeli was blunter about the mechanism: the branded franchise — India, emerging markets, NRT — is now 53% of revenue and structurally more profitable than the group, and “we did not increase the expenses. Expenses are essentially flat this quarter” — Erez Israeli, Executive Officer · 2026-10-23. That, plus R&D at just 6% of sales versus the 7–8% guide, is what produced a 20.6% EBITDA margin. The company is not out-earning the cliff; it is out-spending its own cost line.

Validation is the new goal date

The most useful signal in this transcript is what the keyword record shows rotating. In the company's own momentum history, goal date and Bachupally are among the quarter's biggest decliners, while validation is a top gainer. Curation has moved from the abatacept filing drama to manufacturing execution — and rightly so. Israeli: “The main issue was with our ability to scale up the API. This problem is resolved, and we shipped all the necessary API to our partner. We still need to have the results of the validation.” — Erez Israeli, Executive Officer · 2026-10-23 Analysts initially misread the sequence — Damayanti Kerai of HSBC asked why API would ship before validation — prompting a useful clarification that there are two validations, one on the API and one on the drug product, the latter taking about three weeks.

What has not changed is the volume number. On the prior call Israeli anchored 6–7 million units for calendar 2026 and 12 million pens for FY27; here he repeated “the run rate of 12 to 15 million pens that we discussed in the past still my estimate” — Erez Israeli, Executive Officer · 2026-10-23, and when pushed on whether he felt better, answered flatly that he had not changed his attitude. Meanwhile the market count quietly rose to 89 from the low-80s, Brazil lands in Q4, and — tellingly — price was not mentioned once in the prepared remarks. A quarter ago there was a $25 price floor and a $30 neighbourhood; today it is simply a market outcome. That is the honest read of a molecule heading toward many competitors.

Abatacept: a number, and a flinch

Two genuinely new things happened on Abatacept. First, management quantified US share for the first time: “a fair market share can be any number from 15% to 25%” — Erez Israeli, Executive Officer · 2026-10-23 on the IV formulation, with subcutaneous in February 2028 and the European launch slightly behind the US. Second, and more revealing, the CEO hedged openly in a way he did not in January, when he said they had submitted on time and expected approval toward the end of calendar 2026.

We want to and are preparing to launch in December. If you ask me, is there a chance that we will get a CRL? There is a chance. I do not want to you know, obviously, none of us want it. But there is a chance.

The December 22 goal date is now a binary event for a $11bn market cap. The setup is genuinely attractive — sole biosimilar against the innovator, a medical-benefit product where price sensitivity is lower than pharmacy benefit, and an existing North American commercial frame that management says is already built. The counterweight is the segment's own track record: rituximab sits at Rituximab low single-digit European share and is capacity-constrained, with Israeli declining to promise improvement because the competitive intensity is high. Biosimilars are slow to compound even when they launch.

What management stopped saying

The most instructive part of this quarter is the silence. Dr. Reddy's is one of the few US-exposed generic manufacturers with no tariff refund line at all — astonishing given that Tariff refund was the single hottest keyword in the global cross-section for two consecutive quarters, and peer after peer in this reporting window booked IEEPA recoveries. Instead, the cost pressure came from elsewhere: the Middle East conflict and High fuel costs that dominate the global freight theme, translated into a hit the CFO put at “close to 100 basis points on the EBITDA” — Mannam Venkatanarasimham, Chief Financial Officer · 2026-10-23 from key starting materials, solvents and outbound logistics — and which he expects to persist through Q3 and Q4.

Europe is the other quiet retreat. In January, Israeli was promising that a business under €100mn in 2018 would see "10x this number" in two to three years. Today Europe is €127mn, down 6% year over year, and the guidance is “it will not be significant growth this year” — Erez Israeli, Executive Officer · 2026-10-23, with ex-NRT single digit. The ex NRT qualifier itself is new — a direct consequence of the Haleon carve-out that changed the operating model: “less sales but more profit” — Erez Israeli, Executive Officer · 2026-10-23, with two more quarters of distorted comparatives to run. And buried in the North America discussion is a fresh disclosure that deserves more attention than it got: Bosutinib, a single SKU, has a 180-day exclusivity window that rolls off — the company insists it can absorb the step-down without breaking the sustainability of the current $264mn quarterly run rate.

The CDMO business crossing $100mn on a trailing twelve-month basis is a real milestone, with management targeting a 2–3x multiple in three to four years — broadly consistent with the $250–300mn-by-2030 language from eighteen months ago, so continuity rather than an upgrade. And the business mix argument for margins is credible but self-limiting: flat expenses and 6% R&D cannot be repeated indefinitely, and the CFO conceded R&D must climb back to 7–8%.

So the honest scorecard: the base business is genuinely fixed, the margin is engineered rather than earned, the semaglutide restart is credible but unproven until validation clears, and the entire multiple now rests on a December 22 letter.

maybe by the way, 20 or 21% is not impressive. We always say that we want 25. We are recovering from lenalidomide. And that is what we are going to be. But said it also before. Now I think people believe me.